Biocytogen Pharmaceuticals-B(02315) recommends appointing Liu Hongkang as a non-executive director
Bosaidoo (02315) announced that, following the nomination by the Nomination Committee and the approval by the Board of Directors, it was recommended at the Board meeting held on January 27, 2026 to appoint Mr. Liu Hongkang as a non-executive director.
Biocytogen Pharmaceuticals-B (02315) announced that, following the nomination by the Nomination Committee and approval by the Board of Directors, it was recommended at the Board meeting held on January 27, 2026 to appoint Mr. Liu Hongkang as a non-executive director.
Related Articles
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Guosen: RWA welcomes the era of strict supervision.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Guosen: RWA welcomes the era of strict supervision.
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
